54 completed, 17 terminated, 16 unknown, 14 active not recruiting. 62 Phase 2, 22 Phase 1, 17 Phase 3, 13 Not applicable, 2 Early Phase 1.
Follow this condition Literature Review of Inflammatory Breast Neoplasms trials Research Report on Inflammatory Breast Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Personalized Exercise Program for Survivors of Breast Cancer, STEPS-BC Trial Exercise Intervention, Educational Intervention, Supportive Care - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Not applicable | Recruiting | Wake Forest University Health Sciences | 120 | 2026-10-02 | 2026-10-06 |
| Prediction Of Lymphedema In Patients With Inflammatory BreastCancer Using Preoperative Bioimpedance Measurements Neoadjuvant therapy - Lymphedema, Inflammatory Breast Cancer (IBC) | Recruiting | M.D. Anderson Cancer Center | 150 | 2026-09-16 | 2026-10-02 | |
| Conserving Surgery in Inflammatory Breast Cancer After Neoadjuvant Chemotherapy Breast conserving surgery, Radical modified mastectomy - Inflammatory Breast Cancer | Not applicable | Not yet recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 300 | 2024-03-01 | 2024-01-23 |
| Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study Self-Administered Hypnosis, Self-Administered White Noise Hypnosis - Breast Cancer, Inflammatory Breast Cancer Stage IV | Not applicable | Withdrawn | The University of Tennessee, Knoxville | 2023-09-08 | 2024-05-10 | |
| TRUDI: TDXD+Durva in HER2+/Low IBC Trastuzumab deruxtecan, Durvalumab - Invasive Breast Cancer, Inflammatory Breast Cancer Stage III | Phase 2 | Recruiting | Filipa Lynce, MD | 63 | 2023-05-04 | 2026-10-09 |
| SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer Carboplatin, Pembrolizumab, Transferrin Receptor-Targeted Liposomal p53 cDNA - Anatomic Stage IV Breast Cancer AJCC v8, Breast Inflammatory Carcinoma | Phase 1 | Withdrawn | Northwestern University | 2022-11-10 | 2022-11-15 | |
| Onvansertib + Paclitaxel In TNBC Onvansertib, Paclitaxel - Breast Cancer, Invasive Breast Cancer | Phase 1 / Phase 2 | Active not recruiting | Antonio Giordano, MD | 50 | 2022-09-30 | 2026-02-11 |
| A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC), Pertuzumab IV, Trastuzumab IV - Early Breast Cancer, Locally Advanced Breast Cancer | Phase 3 | Completed | Hoffmann-La Roche | 346 | 2022-07-05 | 2026-02-10 |
| Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer Carboplatin, Cyclophosphamide, Doxorubicin - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2022-03-11 | 2024-10-24 | |
| Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer Eribulin Mesylate, Grapiprant - Breast Inflammatory Carcinoma, Recurrent Breast Inflammatory Carcinoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 6 | 2021-12-21 | 2025-06-13 |
| Refining Local-Regional Therapy for IBC Lymphoscintigraphy - Breast Cancer, Inflammatory Breast Cancer | Not applicable | Recruiting | Dana-Farber Cancer Institute | 50 | 2021-06-02 | 2025-12-29 |
| CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors CT-0508, Pembrolizumab - HER2-positive, Adenocarcinoma | Phase 1 | Unknown | Carisma Therapeutics Inc | 48 | 2021-02-02 | 2024-12-18 |
| FATLAS: Comprehensive Multi-level Characterization of Systemic and Mammary Adiposity in Breast Cancer Patients. Prospective data and sample collection - Breast Neoplasms | Not applicable | Active not recruiting | Universitaire Ziekenhuizen KU Leuven | 150 | 2020-09-01 | 2026-05-18 |
| Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy Atorvastatin, Capecitabine - Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 | Phase 2 | Terminated | M.D. Anderson Cancer Center | 6 | 2019-09-23 | 2024-10-02 |
| Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer MRI - Breast Cancer, HER2-positive Breast Cancer | Not applicable | Active not recruiting | Brigham and Women's Hospital | 214 | 2019-07-26 | 2026-09-09 |
| Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer Biospecimen Collection, Olaparib, Radiation Therapy - Breast Inflammatory Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 300 | 2019-01-18 | 2026-09-29 |
| Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer Pembrolizumab Injection, neoadjuvant EC-paclitaxel chemotherapy - Inflammatory Breast Cancer | Phase 2 | Active not recruiting | Institut Paoli-Calmettes | 52 | 2018-08-29 | 2025-09-12 |
| Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma Indocyanine Green, Lymphangiography, Lymphovenous Bypass - Anatomic Stage III Breast Cancer AJCC v8, Breast Inflammatory Carcinoma | Not applicable | Recruiting | M.D. Anderson Cancer Center | 252 | 2018-08-14 | 2026-05-26 |
| Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer Cyclophosphamide, Doxorubicin, Laboratory Biomarker Analysis - Breast Inflammatory Carcinoma, Locally Advanced Breast Carcinoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 34 | 2018-02-19 | 2026-02-12 |
| Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer Ruxolitinib, Paclitaxel, Doxorubicin - Inflammatory Breast Cancer (IBC) | Phase 2 | Completed | Dana-Farber Cancer Institute | 23 | 2018-01-24 | 2026-07-24 |
Showing 20 of 112. Sign in to see all of them.
Breast Neoplasms (84) · Breast Neoplasms, Male (13) · Triple Negative Breast Neoplasms (13) · Carcinoma, Ductal, Breast (11) · Carcinoma, Lobular (6) · Breast Carcinoma In Situ (5) · Bile Duct Neoplasms (4) · Carcinoma, Hepatocellular (4) · Carcinoma, Non-Small-Cell Lung (4) · Pancreatic Neoplasms (4) · Prostatic Neoplasms (4) · Salivary Gland Neoplasms (4) · Stomach Neoplasms (4) · Carcinoma, Medullary (3)
Breast Diseases (112) · Neoplasms by Site (112) · Skin Diseases (112) · Skin and Connective Tissue Diseases (112) · Neoplasms (110) · Breast Neoplasms (28) · Neoplasms by Histologic Type (23) · Carcinoma (21) · Neoplasms, Glandular and Epithelial (21) · Neoplasms, Ductal, Lobular, and Medullary (17) · Adenocarcinoma (16) · Pathological Conditions, Signs and Symptoms (15) · Carcinoma, Ductal (11) · Pathologic Processes (9) · Signs and Symptoms (7)
Cyclophosphamide (38) · Paclitaxel (22) · Epirubicin (21) · Docetaxel (20) · Trastuzumab (20) · Doxorubicin (19) · Carboplatin (15) · Radiotherapy (13) · Filgrastim (11) · Taxes (11) · Neoadjuvant Therapy (10) · Bevacizumab (9) · Fluorouracil (8) · Albumin-Bound Paclitaxel (7) · Tamoxifen (7)
M.D. Anderson Cancer Center (17) · National Cancer Institute (NCI) (11) · City of Hope Medical Center (6) · GBG Forschungs GmbH (5) · Dana-Farber Cancer Institute (4) · European Organisation for Research and Treatment of Cancer - EORTC (4) · RenJi Hospital (3) · Alliance for Clinical Trials in Oncology (2) · Auxilio Mutuo Cancer Center (2) · Duke University (2) · GlaxoSmithKline (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Memorial Sloan Kettering Cancer Center (2) · Northwestern University (2) · SWOG Cancer Research Network (2)
United States (78) · United Kingdom (10) · Belgium (7) · Canada (7) · Germany (7) · France (6) · China (4) · Puerto Rico (4) · Spain (4) · Tunisia (4) · Chile (3) · Israel (3) · Netherlands (3) · Switzerland (3) · Egypt (2)
Filipa Lynce, MD (3) · George Somlo, MD (3) · Bora Lim, MD (2) · Fernando Cabanillas, MD (2) · Herve Bonnefoi, MD (2) · Joanne Mortimer, MD (2) · Naoto Ueno, MD, PHD (2) · Patrice Viens, MD (2) · A. Bapsi Chakravarthy, MD (1) · Alberto Montero, MD (1) · Amy Subar, Ph.D. (1) · Andreas Schneeweiss, MD, Prof. (1) · Anita Aggarwal, DO, PhD (1)
PMID 34252375, PMID 30976202, PMID 33154826, PMID 38129778, PMID 16274985, PMID 17709827, PMID 18024211, PMID 18474099, PMID 18809612, PMID 19394894, PMID 19433391, PMID 19771508, PMID 19851858, PMID 20214527, PMID 20308670, PMID 20308671, PMID 20623180, PMID 20667781, PMID 21220618, PMID 21570352, PMID 21796368, PMID 22138748, PMID 22198468, PMID 22508812, PMID 22649152, PMID 22915657, PMID 22999386, PMID 24273046, PMID 24618153, PMID 24794243, PMID 25144817, PMID 25199759, PMID 25467016, PMID 25534375, PMID 25943350, PMID 25975632, PMID 26021444, PMID 26063893, PMID 26208483, PMID 26543765, PMID 26869049, PMID 27032301, PMID 27461224, PMID 28315068, PMID 28459938, PMID 28525534, PMID 28715532, PMID 29078273, PMID 29879283, PMID 30528802
P30CA033572 (3), 2016 (2), P30CA015083 (2), P30CA016672 (2), P30CA060553 (2), P30CA072720 (2), U10CA032102 (2), 2008 (1), 2023 (1), N01CM62204 (1), N01CM62205 (1), P30CA008748 (1), P30CA043703 (1), R01CA166020 (1), U01CA062502 (1)